{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-094359","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2024-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.085012+00:00","generated_at":"2026-05-31T10:22:07.704289+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Acasti Pharma Q1 FY2025 net loss $2.6M; STRIVE-ON trial enrollment exceeds 50%","bullets":["Net loss of $2.6M ($0.24 loss per share) vs $4.0M ($0.54) in prior-year quarter.","Cash and equivalents $19.4M as of June 30, 2024; projected runway into Q2 2026.","Pivotal Phase 3 STRIVE-ON safety trial surpassed 50% enrollment; completion expected late 2024 to early 2025.","NDA submission to FDA for GTX-104 anticipated in first half of calendar 2025.","R&D expenses rose to $2.7M from $1.1M, driven by GTX-104 clinical activities."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-094359","json":"https://secwatch.observer/filing/0000950170-24-094359.json","markdown":"https://secwatch.observer/filing/0000950170-24-094359.md","text":"https://secwatch.observer/filing/0000950170-24-094359.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000095017024094359/0000950170-24-094359-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000095017024094359/acst-20240809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:22:07.704289+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}